Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Frontline ALCL news

Graham Collins • 18 May 2020
Lymphoma Brentuximab vedotin

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, of Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses a large data-collection study looking at consecutively diagnosed patients with ALCL and their outcomes following first-line therapy in routine clinical practice. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Graham Collins

1:19
Mechanism of action of BTK degraders and insights into NX-5948
Graham Collins • 16 Jun 2023
1:15
The benefits of glofitamab in R/R DLBCL post-CAR-T therapy
Graham Collins • 16 Jun 2023
1:30
The role of tafasitamab in the lymphoma treatment landscape & promising results from clinical trials
Graham Collins • 16 Jun 2023
1:56
The future of bispecific antibodies in the treatment and management of R/R follicular lymphoma
Graham Collins • 16 Jun 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals